Edition:
United Kingdom

Zhejiang Hisun Pharmaceutical Co Ltd (600267.SS)

600267.SS on Shanghai Stock Exchange

14.20CNY
11 Dec 2017
Change (% chg)

¥0.68 (+5.03%)
Prev Close
¥13.52
Open
¥13.52
Day's High
¥14.30
Day's Low
¥13.52
Volume
12,094,990
Avg. Vol
7,650,497
52-wk High
¥16.70
52-wk Low
¥10.24

Select another date:

Tue, Nov 28 2017

BRIEF-Zhejiang Hisun Pharmaceutical's share trade to resume after Pfizer exited China JV

* SAYS SHARE TRADE TO RESUME ON NOV 29 AFTER PFIZER EXITED CHINA JOINT VENTURE WITH THE COMPANY Source text in Chinese: http://bit.ly/2iZ534b Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang Hisun Pharmaceutical passes FDA approval

* Says it received approval for a kind of tablet from U.S Food and Drug Administration

BRIEF-Zhejiang Hisun Pharmaceutical to issue up to 3.0 bln yuan commercial paper

* Says it plans to issue up to 3.0 billion yuan ($452.59 million) ultra-short commercial paper

BRIEF-Zhejiang Hisun Pharmaceutical unit says product gets FDA approval

* Says co's Hangzhou-based unit's product simvastatin tablets, gets approval from U.S. Food and Drug Administration

Pfizer exits China joint venture for generic drugs

Pfizer Inc said on Friday it has sold its 49 percent stake to exit a joint venture it had set up with China's Zhejiang Hisun Pharmaceuticals in 2012 to develop and market generic drugs.

Pfizer exits China joint venture for generic drugs

Nov 10 Pfizer Inc said on Friday it has sold its 49 percent stake to exit a joint venture it had set up with China's Zhejiang Hisun Pharmaceuticals in 2012 to develop and market generic drugs.

BRIEF-Zhejiang Hisun Pharmaceutical receives TGA-GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Therapeutic Goods Administration

BRIEF-Zhejiang Hisun Pharmaceutical to invest 5.1 mln yuan to set up investment management JV

* Says it will invest 5.1 million yuan to set up Zhejiang-based investment management JV, which will be engaged in operation of pharmaceutical industry innovation projects, and hold 51 percent stake in JV after transaction

BRIEF-Zhejiang Hisun Pharmaceutical plans to sell stake in Germany's INS

* Says it plans to sell its entire 21.05 percent stake in Germany's IMD Natural Solutions GmbH (INS)

BRIEF-Zhejiang Hisun Pharmaceutical sub-subsidiary passes FDA approval

* Says its Zhejiang-based sub-subsidiary received FDA approval for metformin sustained release tablet from U.S Food and Drug Administration

Select another date: